What next for CRISPR after first therapeutic approvals?
As we celebrate the first regulatory approval of a gene-editing based therapeutic, Casgevy™, for the treatment of sickle cell disease and transfusion-dependent β-thalassemia, we consider the gene-editing challenges that must be overcome before CRISPR gene-editing technology becomes a common treatment modality